Dr. Jacob S. Thomas
Medical Oncology (Medical Oncology Physician)
1441 Eastlake Ave
Los Angeles, CA 90089
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 127
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A129536 (first issued 2014; current) -
Hematology & Oncology Physician
CA license A129536 (first issued 2014; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Keck Hospital of Usc Los Angeles, CA
- Los Angeles General Medical Center Los Angeles, CA
Medical groups
- Usc Care Medical Group Inc (1,380 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 127
- Services billed
- 885
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 299 | 71 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 92 | 34 |
| Established patient office or other outpatient visit, 20-29 minutes | 77 | 45 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
| Hospital discharge day management, 30 minutes or less | 19 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Los Angeles, CA | 34 |
| Lenvima (lenvatinib mesylate) | 23 |
| Gabapentin Other prescribers in Los Angeles, CA | 22 |
| Ondansetron Hcl Other prescribers in Los Angeles, CA | 19 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Los Angeles, CA | 18 |
| Prednisone Other prescribers in Los Angeles, CA | 17 |
| Retevmo (selpercatinib) | 17 |
| Lumakras (sotorasib) | 14 |
| Pantoprazole Sodium Other prescribers in Los Angeles, CA | 13 |
| Tafinlar (dabrafenib mesylate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $69.18 in total to this clinician.
| Beone Medicines USA, Inc. | $47.75 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $21.43 |
| Food and Beverage | $69.18 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $119,017 in research payments for these studies, mostly to the institutions running them.
- An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Beone Medicines USA, Inc. · Recruiting · NCT06589596 - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc. · Completed · NCT05103358 - A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.